



Company Overview

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo's Universal AMPICOLLECT™ Used on GENFLEX® Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization

Apr 21 2021, 8:00 AM EDT

ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUM

Mar 17 2021, 4:15 PM EDT

Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates

Mar 15 2021, 4:05 PM EDT

Stock Overview

Symbol	ENZ
Exchange	NYSE
Market Cap	144.69m
Last Price	\$3.00
52-Week Range	\$1.80 - \$4.85

05/07/2021 04:00 PM EDT

Investor Relations

IR@enzo.com

Management Team

Elazar Rabbani, PhD

Chairman of the Board of Directors & Chief Executive Officer

Barry W. Weiner

President

David Bench

Chief Financial Officer

Kara Cannon

Chief Commercial Officer

Dieter Schapfel, MD

Chief Medical Officer

Enzo Biochem, Inc.

527 Madison Avenue
New York, NY 10022

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.